This inventor holds 2 USPTO granted patents, plus 2 CIPO patents and 2 EPO patents. Top assignee: Natco Pharma Limited. Active years: 2011.
Company Filing History:
Years Active: 2011
Title: **Innovative Contributions of Khadgapathi Podili in Pharmaceuticals**
Introduction:
Khadgapathi Podili is a notable inventor based in Hyderabad, Telangana, India, who has made significant contributions to the field of pharmaceuticals. With two registered patents, his innovative work focuses on improving treatments for Chronic Myelogenous Leukemia (CML).
Latest Patents:
Khadgapathi Podili's latest patents include:
1. **Polymorphic form of imatinib mesylate and a process for its preparation**: This invention reveals a novel stable crystal form of imatinib mesylate, designated as α-Form. It is stable at room temperature and can withstand higher temperatures up to 120°C and accelerated stress conditions, being freely soluble in water. The pharmaceutical composition derived from this invention contains the α-form and other typical excipients, proving useful in CML treatment. The preparation process involves slurrying Imatinib base in isopropanol at room temperature, adding methane sulfonic acid, and maintaining temperatures between 50-60°C before filtration. The invention also details a process to create this stable α-crystalline form by converting Imatinib mesylate β-polymorphic modification through suspending it in water and organic solvents, distilling off water azeotropically, cooling, and filtering to produce the α-crystal form.
2. **Phenylaminopyrimidine derivatives as inhibitors of BCR-ABL kinase**: This invention relates to novel intermediates essential for preparing new phenylaminopyrimidine derivatives. These compounds, characterized by their therapeutic potential, are particularly useful in the treatment of CML with IC₅₀ values ranging from 0.1 to 10.0 nm.
Career Highlights:
Khadgapathi Podili is affiliated with Natco Pharma Limited, where he utilizes his expertise in pharmaceutical innovation. His work focuses on developing novel compounds that significantly enhance treatment options in oncology, specifically targeting CML.
Collaborations:
Throughout his career, Khadgapathi has collaborated closely with notable colleagues such as Bhujanga Rao Adibhatla, Kali Satya, and Sreenivas Rachakonda. These collaborations have fostered an environment of innovation and advancement in pharmaceutical development.
Conclusion:
Khadgapathi Podili's inventive spirit and dedication to research have enabled significant advancements in the pharmaceutical industry. His patents not only contribute to the scientific community but also offer hope for improved treatment options for patients suffering from Chronic Myelogenous Leukemia. His ongoing work promises to continue shaping the future of medicinal therapies.